Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year

Oral weekly regimen (3 days on/4 days off) at 120 mg and 160 mg QD dose levels selected for randomized dose optimization across AP3-informed solid tumor populations